Celldex Therapeutics (CLDX) Change in Acquisitions & Divestments (2010 - 2026)

Celldex Therapeutics' Change in Acquisitions & Divestments history runs 17 years deep, the most recent figure standing at $133.4 million for Q1 2026.

• On a quarterly basis, Change in Acquisitions & Divestments fell 31.62% year-over-year to $133.4 million in Q1 2026; TTM through Mar 2026 was $534.6 million, a 13.69% decrease from a year earlier, with the FY2025 full-year figure at $596.3 million, up 18.85% from the prior year.
• Change in Acquisitions & Divestments improved to $133.4 million in Q1 2026 per CLDX's latest filing, from $111.5 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $195.0 million in Q1 2025 and bottomed at $27.8 million in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $111.5 million (2025), against an average of $107.8 million.
• Biggest YoY gain for Change in Acquisitions & Divestments was 562.38% in 2022; the steepest drop was 64.3% in 2022.
• Year by year, Change in Acquisitions & Divestments stood at $87.8 million in 2022, then fell by 19.26% to $70.9 million in 2023, then soared by 117.2% to $154.0 million in 2024, then retreated by 27.59% to $111.5 million in 2025, then climbed by 19.61% to $133.4 million in 2026.
• Per Business Quant, the three latest CLDX Change in Acquisitions & Divestments figures stand at $133.4 million (Q1 2026), $111.5 million (Q4 2025), and $116.9 million (Q3 2025).